Desmoid Tumors account for less than
3% of soft tissue tumors. According to orpha.net, the annual Desmoid tumors incidence
is estimated to range between 1/250,000-1/500,000. These tumors more
predominantly affect women between the ages of 15-60 years.
Soft Tissue Sarcomas (STS) is a family
of rare, mesenchymal (connective tissue) neoplasms with heterogeneous differentiation
and may arise in various organs (including fat, muscle, nerve and nerve sheath,
blood vessels, and other connective tissue).
As per the American Cancer Society’s
estimates, a slight male preponderance is observed over the female, although this
difference is rarely statistically significant.
These tumors develop mainly in adults
around the age of 50, the frequency increases with age; and 10% of patients are
children and adolescents.
The market outlook and treatment landscape of STS have changed dramatically in the last decades, with advances in the diagnosis of subtyping and with the introduction of targeted therapies. The treatment market is segmented into surgery, radiation therapy, chemotherapy, anti-angiogenesis drugs and targeted therapy.
Sarcoma treatment landscape has changed dramatically in the last few years with the introduction of targeted therapies.
Evotec-
Germany based pharma company has entered into a collaboration with Japan’s
Takeda Pharmaceutical for the development of at least five drug discovery
programs across a broad range of indications.
Under the terms of the agreement, Evotec will use its integrated drug discovery program to advance Takeda’s therapeutic areas namely oncology, gastroenterology, neuroscience and rare diseases.
Evotec is planning to use the drug
discovery platform to accelerate small molecule programs. Once Evotec is able
to produce a drug candidate, Takeda will have the option to fully acquire it.
Furthermore, Takeda will pay Evotec the amount upfront one-time to gain access to the latter’s platform. Whereas, Evotec is eligible to gain an amount of USD 170 million for achieving each milestone in addition to realities on the sales.
The US FDA has given its recommendation for Jynneos Smallpox and Monkeypox Vaccine, to be used for the prevention of monkeypox and smallpox in adults aged 18 years and above.
Manufactured by Bavarian Nordic, this is the only present vaccine which is FDA-approved for the prevention of monkeypox and smallpox.
Smallpox is a viral infection caused by Variola virus with fatality rates approximately 30% overall, although survivors frequently suffered significant morbidity including blindness and skin scarring, as per NCBI.
Smallpox
is in existence for over 3,000 years and was considered the global threat until
it was eradicated by a collective global vaccination programme led by the World
Health Organization.
However, it still remains the most feared disease due to the nature of a highly contagious virus.
The
monkeypox virus is similar to human smallpox, however, monkeypox virus is much trivial
than smallpox, but it can be fatal.
The
vaccine will be administered to people who are at high risk of either of the
diseases.
Jynneos
vaccine is a part of the Strategic National Stockpile (SNS), which will ensure
it easy and convenient accessibility to the masses in the US.
